OLINVO™ (oliceridine injection), our lead product candidate with FDA Breakthrough Therapy Designation, is a next generation IV analgesic in development for the management of moderate-to-severe acute pain.
Our pipeline includes several additional product candidates we have identified as potential best- or first-in-class therapies for a variety of critical unmet medical needs. These are all new molecules discovered by Trevena scientists using our proprietary ABLE™ platform.
July 12, 2017Trevena to Host Analyst Day on July 20, 2017
Copyright © Trevena, Inc.